Gilead presented data on the safety of its long-acting ARV drug
Last Thursday, March 7, on the closing day of the International Conference on Retroviruses and Opportunistic Infections (CROI2019), the first data on the safety and tolerability of a fundamentally new ART-medication of prolonged action GS-6207 were presented. The development of the pharmaceutical company Gilead Sciences is a selective multistage capsid inhibitor HIV molecule.
9 märts 2019 15:35
Mortality from breast cancer is more common among women with HIV
According to a cohort study presented at the Conference on Retroviruses and Opportunistic Infections (CROI2019) in Seattle, the mortality rate among HIV-positive women with breast cancer (BC) is higher than among those with a negative status.
Lugege edasi
8 märts 2019 15:53
Test and Treat Principle Reduces the Number of New HIV Cases in South Africa by 30%
According to the latest data presented at the Conference on Retroviruses and Opportunistic Infections (CROI2019), the number of new HIV infections in southern Africa can be significantly reduced by voluntary testing for HIV in communities and immediately ...
Lugege edasi
Mis on Life4me+?
Üks Life4me+ peamiseid eesmärke on uute HIVi- ja muude sugulisel teel levivate nakkuste juhtumite, nagu ka C-hepatiiti ja tuberkuloosi nakatumise ennetamine. Seepärast räägime HIVist ja muudest haigustest — sellest, kuidas end nende eest kaitsta ja kuidas elada nakatununa.
Rohkem
Kampaania Life4me+
Info haridusliku kampaania "M = M" kohta ("Mittetuvastatav = mitteedasikanduv", #UequalsU, #НравноН), mis on Life4me+ poolt organiseeritud Ida-Euroopas ja Kesk-Aasias regioonis, suunatud info levitamisele, et HIV-positiivne inimene mittetuvastatava viiruskoormusega ei saa viirust seksuaalsel teel edasi kanda teisele inimesele.
Mitmed uuringud on näidanud, et diskordantses paaris, kus HIV-positiive partner võtab ARV ravimeid ja hoiab viiruskoormuse mittetuvastataval tasemel, ei ole teada juhtumitest, kus HIV oleks seksuaalsel teel edasi kandunud.
Meie partnerid
